Re-Examining the Pharmacogenetics of Clozapine—A Critical Evaluation

Clozapine remains the only antipsychotic with proven superiority for treatment-resistant schizophrenia, yet its use is constrained by marked interindividual variability in both response and toxicity and by a burdensome adverse-effect profile spanning agranulocytosis, myocarditis, and metabolic syndrome. Three decades of pharmacogenetic research have sought genetic markers capable of predicting, before treatment begins, who will respond and who will suffer harm. This narrative review critically re-examines that record across three domains: pharmacokinetics (metabolism and transport), pharmacodynamics (treatment response), and adverse drug reactions, before evaluating the gap between research findings and clinical implementation. Pharmacokinetic pharmacogenetics has been the field’s most consistent disappointment: CYP1A2 genotype contributes little beyond smoking status, and CYP2C19 and ABCB1 variants exert only modest effects on plasma concentrations. Pharmacodynamic pharmacogenetics has fared no better; candidate genes in the serotonergic and dopaminergic systems, including the celebrated six-single-nucleotide-polymorphism response model, have failed replication in genome-wide and independent cohorts. Only the adverse-reaction domain has yielded durable findings: HLA-DQB1 126Q, HLA-B 158T, and population-specific alleles such as HLA-B*59:01 are biologically coherent and replicated correlates of clozapine-induced agranulocytosis, yet their predictive values remain too low to alter mandatory hematological monitoring. This review identifies five recurring methodological failures underlying this pattern of underdelivery: chronically inadequate sample sizes, phenotype heterogeneity, inadequately handled population stratification, conflation of biological plausibility with clinical evidence, and a translational logic gap between statistical association and actionable prediction. No genetic marker or panel currently meets the evidentiary threshold required to guide clozapine initiation, dosing, or monitoring. Therapeutic drug monitoring informed by smoking status already delivers much of what pharmacogenetics promises, at lower cost and with more direct capture of the dominant determinants of clozapine exposure. Large, adequately powered, trans-ancestral genome-wide studies, evaluated against prospective clinically meaningful outcomes, are needed before genetic testing can be considered ready for clozapine prescribing decisions.